Related references
Note: Only part of the references are listed.The preoperative controlling nutritional status (CONUT) score is an independent prognostic marker for pancreatic ductal adenocarcinoma
Fumihiro Terasaki et al.
UPDATES IN SURGERY (2021)
Validation and clinical usefulness of pre- and postoperative systemic inflammatory parameters as prognostic markers in patients with potentially resectable pancreatic cancer
Sojun Hoshimoto et al.
PANCREATOLOGY (2020)
Multicentre study of multidisciplinary team assessment of pancreatic cancer resectability and treatment allocation
J. Kirkegard et al.
BRITISH JOURNAL OF SURGERY (2019)
Optimizing the outcomes of pancreatic cancer surgery
Oliver Strobel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
A Novel Physiobiological Parameter-Based Grading System for Resectable Pancreatic Cancer
Takehiro Okabayashi et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time
Caroline J. Rieser et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Validation of at least 1 mm as cut-off for resection margins for pancreatic adenocarcinoma of the body and tail
T. Hank et al.
BRITISH JOURNAL OF SURGERY (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter Study
Ho Won Kang et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2017)
Pancreatic Adenocarcinoma, Version 2.2017
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al.
LANCET (2017)
Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis
Qingcai Meng et al.
ONCOTARGETS AND THERAPY (2017)
The Charlson age comorbidity index predicts prognosis in patients with resected pancreatic cancer
Tomonari Asano et al.
INTERNATIONAL JOURNAL OF SURGERY (2017)
Pancreatic Cancer Surgery The New R-status Counts
Oliver Strobel et al.
ANNALS OF SURGERY (2017)
Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study
John R. Bergquist et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2016)
Pancreatic cancer
Jorg Kleeff et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement
Gary S. Collins et al.
ANNALS OF INTERNAL MEDICINE (2015)
Pancreatic Adenocarcinoma Number of Positive Nodes Allows to Distinguish Several N Categories
Oliver Strobel et al.
ANNALS OF SURGERY (2015)
Long-Term Survival Rates after Resection for Locally Advanced Kidney Cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 Experience
Wassim M. Bazzi et al.
JOURNAL OF UROLOGY (2015)
The Charlson age comorbidity index predicts early mortality after surgery for pancreatic cancer
Daniela Dias-Santos et al.
SURGERY (2015)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: A consensus statement by the International Study Group on Pancreatic Surgery (ISGPS)
Johanna A. M. G. Tol et al.
SURGERY (2014)
Extended pancreatectomy in pancreatic ductal adenocarcinoma: Definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS)
Werner Hartwig et al.
SURGERY (2014)
Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)
Maximilian Bockhorn et al.
SURGERY (2014)
CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative Therapy
Werner Hartwig et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancer
Donald C. McMillan
CANCER TREATMENT REVIEWS (2013)
Artery-first' approaches to pancreatoduodenectomy
P. Sanjay et al.
BRITISH JOURNAL OF SURGERY (2012)
Pancreatic Cancer Surgery in the New Millennium Better Prediction of Outcome
Werner Hartwig et al.
ANNALS OF SURGERY (2011)
An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study
M. J. Proctor et al.
BRITISH JOURNAL OF CANCER (2011)
A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study
Michael J. Proctor et al.
EUROPEAN JOURNAL OF CANCER (2011)
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial
John P. Neoptolemos et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Share Paper
